艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性
合集下载
相关主题
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
-94- 中华医学·炎证·毒邪热结
Clinical Journal of Chinese Medicine 2018 Vol.(10) No.24
艾拉莫德与羟氯喹治疗干燥综合征患者疗效及 安全性
wenku.baidu.com
Efficacy and safety of elamod and hydroxychloroquine in the treatment of patients with dry syndrome
干燥综合征是一种慢性炎性反应性自身免疫疾病，病变累 及外分泌腺体，如泪腺、唾液腺等，并能侵犯机体其他组织及 器官。本病的发病机制尚未明确，临床以中年女性最为多见， 表现为口、眼部位干燥，临床治疗多以人工唾液及泪液对症治 疗，效果有限。近年来临床研究显示，B 细胞多克隆性免疫增 生导致多种自身抗体及免疫球蛋白增多，是发病的重要原因[1]。 艾拉莫德为新型抗风湿免疫药物，能抑制 B 细胞产生 IgG、IgM， 减少炎性因子的表达，达到缓解症状的效果。羟氯喹可改善高 球蛋白血症，缓解本病引起的关节肌肉疼痛[2]。本研究对比分 析艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性，现具 体汇报如下。
罗绮雯 郭冬梅 余旸弢 林嘉鸿 （佛山市第一人民医院，广东 佛山，528000）
中图分类号：R442.8 文献标识码：A 文章编号：1674-7860（2018）24-0094-02 证型：IGB
【摘 要】目的：探讨艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性。方法：将 2016 年 8 月—2017 年 8 月在我院风 湿免疫科治疗的 80 例干燥综合征患者随机分为两组，均服用甲泼尼龙治疗，在此基础上，对照组使用羟氯喹治疗，观察组使用艾 拉莫德治疗，比较两组患者的临床疗效、各项风湿免疫指标变化、安全性。结果：观察组治疗总有效率为 92.5%，明显高于对照 组的 72.5%，差异有统计学意义（P＜0.05）；观察组治疗后 ESR、IgG、RF、PLT 水平与对照组相比明显改善，差异有统计学意义 （P＜0.05）；观察组在胃肠道反应、皮疹、瘙痒、肝功能异常、白细胞降低等不良反应发生率上与对照组相比无明显差异（P＞0.05）。 结论：艾拉莫德治疗干燥综合征的疗效更佳，有效降低 B 细胞活性，降低 IgG 水平，且对胆碱酯酶的活性抑制力更强，能够增加 泪液及唾液的分泌，具有积极的临床意义。
【关键词】干燥综合征；艾拉莫德；羟氯喹；疗效及安全性 【Abstract】Objective: To explore the efficacy and safety of elamod and hydroxychloroquine in the treatment of patients with dry syndrome. Methods: 80 cases of patients with dry syndrome treated in our hospital from August 2016 to August 2017 were randomly divided into two groups, both groups received prednisolone treatment, on this basis, the control group was given hydroxychloroquine treatment, the observation group was treated with elamod, the clinical efficacy, the rheumatoid immune indexes change, and security of two groups of patients were compared. Results: The therapeutic efficiency of the observation group was 92.5%, which was significantly higher than that of the control group, 72.5%, and the difference was statistically significant (P＜0.05). The ESR, IgG, RF and PLT levels of the observation group were significantly improved after treatment compared with those of the control group (P＜0.05). There was no significant difference between the observation group and the control group in the incidence of adverse reactions including gastrointestinal reaction, skin rash, pruritus, abnormal liver function, and decreased white blood cells (P＞0.05). Conclusion: Elamod was more effective in treating dry syndrome, it could effectively reduce the activity of B cells, reduce IgG level, and inhibit the activity of cholinesterase more strongly. It could increase the secretion of tears and saliva, which had positive clinical significance. 【Keywords】Dry syndrome; Elamod; Hydroxychloroquine; Efficacy and safety doi:10.3969/j.issn.1674-7860.2018.24.041
Clinical Journal of Chinese Medicine 2018 Vol.(10) No.24
艾拉莫德与羟氯喹治疗干燥综合征患者疗效及 安全性
wenku.baidu.com
Efficacy and safety of elamod and hydroxychloroquine in the treatment of patients with dry syndrome
干燥综合征是一种慢性炎性反应性自身免疫疾病，病变累 及外分泌腺体，如泪腺、唾液腺等，并能侵犯机体其他组织及 器官。本病的发病机制尚未明确，临床以中年女性最为多见， 表现为口、眼部位干燥，临床治疗多以人工唾液及泪液对症治 疗，效果有限。近年来临床研究显示，B 细胞多克隆性免疫增 生导致多种自身抗体及免疫球蛋白增多，是发病的重要原因[1]。 艾拉莫德为新型抗风湿免疫药物，能抑制 B 细胞产生 IgG、IgM， 减少炎性因子的表达，达到缓解症状的效果。羟氯喹可改善高 球蛋白血症，缓解本病引起的关节肌肉疼痛[2]。本研究对比分 析艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性，现具 体汇报如下。
罗绮雯 郭冬梅 余旸弢 林嘉鸿 （佛山市第一人民医院，广东 佛山，528000）
中图分类号：R442.8 文献标识码：A 文章编号：1674-7860（2018）24-0094-02 证型：IGB
【摘 要】目的：探讨艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性。方法：将 2016 年 8 月—2017 年 8 月在我院风 湿免疫科治疗的 80 例干燥综合征患者随机分为两组，均服用甲泼尼龙治疗，在此基础上，对照组使用羟氯喹治疗，观察组使用艾 拉莫德治疗，比较两组患者的临床疗效、各项风湿免疫指标变化、安全性。结果：观察组治疗总有效率为 92.5%，明显高于对照 组的 72.5%，差异有统计学意义（P＜0.05）；观察组治疗后 ESR、IgG、RF、PLT 水平与对照组相比明显改善，差异有统计学意义 （P＜0.05）；观察组在胃肠道反应、皮疹、瘙痒、肝功能异常、白细胞降低等不良反应发生率上与对照组相比无明显差异（P＞0.05）。 结论：艾拉莫德治疗干燥综合征的疗效更佳，有效降低 B 细胞活性，降低 IgG 水平，且对胆碱酯酶的活性抑制力更强，能够增加 泪液及唾液的分泌，具有积极的临床意义。
【关键词】干燥综合征；艾拉莫德；羟氯喹；疗效及安全性 【Abstract】Objective: To explore the efficacy and safety of elamod and hydroxychloroquine in the treatment of patients with dry syndrome. Methods: 80 cases of patients with dry syndrome treated in our hospital from August 2016 to August 2017 were randomly divided into two groups, both groups received prednisolone treatment, on this basis, the control group was given hydroxychloroquine treatment, the observation group was treated with elamod, the clinical efficacy, the rheumatoid immune indexes change, and security of two groups of patients were compared. Results: The therapeutic efficiency of the observation group was 92.5%, which was significantly higher than that of the control group, 72.5%, and the difference was statistically significant (P＜0.05). The ESR, IgG, RF and PLT levels of the observation group were significantly improved after treatment compared with those of the control group (P＜0.05). There was no significant difference between the observation group and the control group in the incidence of adverse reactions including gastrointestinal reaction, skin rash, pruritus, abnormal liver function, and decreased white blood cells (P＞0.05). Conclusion: Elamod was more effective in treating dry syndrome, it could effectively reduce the activity of B cells, reduce IgG level, and inhibit the activity of cholinesterase more strongly. It could increase the secretion of tears and saliva, which had positive clinical significance. 【Keywords】Dry syndrome; Elamod; Hydroxychloroquine; Efficacy and safety doi:10.3969/j.issn.1674-7860.2018.24.041